Research from Hardman & Co, Hardman & Co

Hardman & Co

Hardman & Co has a long established reputation for high quality and independent research on small and mid cap quoted companies. Our industry analysts are all highly experienced, with an average of 23 years researching companies for investors. In addition to providing in-depth company coverage, we work closely with our clients in an advisory capacity, providing market intelligence, advice on corporate transactions and in constructing marketing programmes targeted at both retail and institutional investors. 
 
The research we produce is published in both hard and soft copy through a variety of channels, including our bespoke global distribution list, Bloomberg, Thomson Reuters, RNS-Reach and FactSet. 

Sectors: 

- Agriculture
- Building & Construction
- Business Services
- Education
- Financial Services
- Life Sciences
- Media
- Mining
- Oil & Gas
- Property
- Renewables
- Retail Bonds
- Technology
- Utilities 

Other services include: Corporate Research, Valuation Services, Investor Engagement and Hardman Agribusiness.

Research from Hardman & Co

Investment research on quoted companies and funds

Hardman

Hardman & Co is a multi-disciplinary financial consultancy and investment research firm, employing highly experienced analysts and professionals with a broad range of capital markets expertise. Our clients are public and private businesses as well as fund managers, ranging from start-ups to £1 billion+ market capitalisations.

Hardman & Co offers corporate research & consultancy, serving the needs of both public and private companies. We produce gold-standard research with a global reach for trading and investment companies, as well as providing market commentary and analysis. In addition, we carry out a number of bespoke investment-related assignments, including due diligence on bond listings, assessments of private company valuations and other corporate advisory services. We engage with the market through traditional and digital media, offering illuminating video content on corporate management strategy, results communication, interviews and in-house sector discussion.

Equity Bottom-Up

<ul><li>Shield is a commercial-stage pharma company delivering specialty products that address patients’ unmet medical needs, with an initial focus on iron deficiency (ID).</li><li>Positive Rx momentum in 2022 started to accelerate at the end of 1Q’23 and has continued into 3Q’23, following expansion of the Shield-Viatris commercial team.</li><li>In the event that the US goals are achieved, there would be considerable upside potential to the valuation.</li></ul>

Shield is a commercial-stage pharma company delivering specialty products that address patients’ unmet medical needs, with an initial focus on iron deficiency (ID).Positive Rx momentum in 2022 started to accelerate at the end of 1Q’23 and has continued into 3Q’23, following expansion of the Shield-Viatris commercial team.In the event that the US goals are achieved, there would be considerable upside potential to the valuation.

Hardman & Co Research: Shield Therapeutics (STX): Accelerating effectiveness of enlarged sales team